Simple blood test may predict deadly transplant complication

NCT ID NCT05718791

Recruiting now Knowledge-focused Sponsor: Henry Ford Health System Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether two blood markers, CXCL9 and EASIX, can predict severe acute graft-versus-host disease (GVHD) after a stem cell transplant. Researchers will take blood samples from 100 adult patients 28 days after transplant to see if these markers can spot early signs of GVHD. The goal is to help doctors make better decisions and improve transplant success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that helps doctors predict and prevent severe graft-versus-host disease before it starts.
What could go wrong: This is a small, early-stage study (100 participants) that only measures markers at one time point. The results may not apply to all patients or lead to a reliable prediction tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GVHD, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD, ACUTE

Contacts and locations

Locations

Henry Ford Health System
RECRUITING

Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.